In both adults with and without self-reported COPD, a 6- or 12-week course of cytisinicline helped more daily smokers achieve ...
A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
She told us her life changed when she sought treatment at Christ Hospital and met Dr. Duane Allen, a pulmonary and critical ...
NEW JERSEY (Ivanhoe Newswire) – According to the Centers for Disease Control and Prevention, COPD, or chronic obstructive pulmonary disease was the sixth leading cause of death in the U.S. in 2020.
Clinical Trials Arena on MSN
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.
Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...
David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...
Hosted on MSN
First new treatment for asthma attacks in 50 years
An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published in The ...
Please provide your email address to receive an email when new articles are posted on . During a 5-year period, 45,079 of 156,462 patients with GOLD A/B COPD progressed to GOLD E. More patients moved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results